PMID- 19520676
OWN - NLM
STAT- MEDLINE
DCOM- 20100309
LR  - 20091113
IS  - 1938-2723 (Electronic)
IS  - 1076-0296 (Linking)
VI  - 15
IP  - 5
DP  - 2009 Oct
TI  - Economic and practical aspects of thromboprophylaxis with unfractionated and 
      low-molecular-weight heparins in hospitalized medical patients.
PG  - 489-500
LID - 10.1177/1076029609335910 [doi]
AB  - Acutely ill medical patients are at significant risk of developing venous 
      thromboembolic (VTE) complications during or after their hospitalization. Venous 
      thromboembolic events, such as proximal deep vein thrombosis (DVT) or pulmonary 
      embolism (PE), place a high and unacceptable burden on health care resources, up 
      to US$1.5 billion annually in the United States. However, the burden of VTE can 
      be reduced by use of appropriate thromboprophylaxis. Prophylaxis of VTE with 
      either a low-dose unfractionated heparin (UFH) or a low-molecular-weight heparin 
      (LMWH) in medical inpatients is effective, well tolerated and cost-effective, 
      compared with no prophylaxis. Low-molecular-weight heparins have a number of 
      practical benefits over UFH, including once-daily subcutaneous injection and the 
      potential to be used in the outpatient setting. These clinical advantages could 
      translate to improved patient adherence to therapy and provide economic benefits, 
      where LMWHs are more cost-effective compared with UFH.
FAU - Pineo, Graham F
AU  - Pineo GF
AD  - From the University of Calgary, Alberta, Canada. 
      graham.pineo@calgaryhealthregion.ca
FAU - Hull, Russell D
AU  - Hull RD
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20090610
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 0 (Heparin, Low-Molecular-Weight)
SB  - IM
MH  - Cost-Benefit Analysis
MH  - Heparin, Low-Molecular-Weight/*economics/*therapeutic use
MH  - Humans
MH  - Postoperative Care/economics/methods
MH  - Postoperative Complications/prevention & control
MH  - Risk Factors
MH  - Venous Thromboembolism/drug therapy/*economics/*prevention & control
RF  - 71
EDAT- 2009/06/13 09:00
MHDA- 2010/03/10 06:00
CRDT- 2009/06/13 09:00
PHST- 2009/06/13 09:00 [entrez]
PHST- 2009/06/13 09:00 [pubmed]
PHST- 2010/03/10 06:00 [medline]
AID - 1076029609335910 [pii]
AID - 10.1177/1076029609335910 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2009 Oct;15(5):489-500. doi: 10.1177/1076029609335910. 
      Epub 2009 Jun 10.